April 4, 2018
AstraZeneca’s leukemia drug, Moxetumomab pasudotox has received Priority Review designation from the US FDA for the treatment of adult patients ...
Access articles & resources worth up to US $4, 000 per month.
Most up-to-date information, original and in-depth reviews, full-length exclusive market reports and forecasts, full-access to the smart knowledge base centres, useful resources and databases.
Access articles & resources worth up to $4000.
AstraZeneca Commits $90 Million in 5 Years to Improve Healthcare in India
First-of-its-Kind FDA-Cleared Device Launched to Enhance Tear Production
Delhi-Based Healthcare Fintech Startup Raises $1 M in Seed Funding Round
First AI-Based Diabetic Retinopathy Detection Device Gets FDA Approval
7 New Ideas to Start a Healthcare Business in India (2018)
Pharma Patents: Can India Reward Incremental Innovation?